Sanofi to acquire Kymab
Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, have entered into an agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.
Kymab receives $9m grant from the Bill & Melinda Gates Foundation
Kymab Group Limited, a leading monoclonal antibody biopharmaceutical group, announced today that it has received a $9m grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.
Antibody shows dramatic post-transplant benefit in animal model
Kymab's new therapeutic antibody for autoimmune diseases, KY1005, shows potential for improvement in post-transplant survival in an animal model of Graft-versus-Host Disease.
Kymab secures US$100 million Series C funding
Kymab Group Limited, a leading monoclonal antibody biopharmaceutical group, announced that it has successfully secured a US$100 million (£81 million) Series C financing.
Kymab signs bispecific antibody agreement with EpimAb
Kymab Limited, a leading human monoclonal antibody biopharmaceutical company based at the Babraham Research Campus, and EpimAb Biotherapeutics, Inc., an emerging Chinese biopharmaceutical company specialising in bispecific antibodies, today announced a cross-licensing and development agreement to develop bispecific therapeutic antibodies against multiple targets.
Kymab secures US $40 million investment
Kymab secures US $40 million investment from two of the largest foundations in the world to advance clinical development of antibody therapeutics. Series B Financing includes the Wellcome Trust and the Bill & Melinda Gates Foundation.